<unk>  (short for Cancer Vaccine), is an immunotherapeutic agent that was first developed in Australia.<unk>  was developed by the biotechnology company Prima BioMed (Nasdaq: PBMD) through to Phase II clinical studies between 2001 and 2015. After inconclusive clinical data in ovarian cancer 2013 and 2014, Prima announced in February 2015 that it had ceased recruiting into<unk>  clinical studies and was seeking commercial partners for the product.
CVac
CVAC
BMJ 
Nice
Port 
IHunch
Bleb 
PRO-LAD